deltatrials
Completed PHASE3 NCT00050232

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Sponsor: Avanir Pharmaceuticals

Conditions Multiple Sclerosis
Interventions AVP-923
Updated 6 times since 2017 Last updated: Jul 13, 2016 Started: Dec 31, 2002 Primary completion: Jun 30, 2004 Completion: Jun 30, 2004

This PHASE3 trial investigates Multiple Sclerosis and is currently completed. Avanir Pharmaceuticals leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Avanir Pharmaceuticals
Data source: Avanir Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Allentown, United States, Amherst, United States, Burlington, United States, Canton, United States, Decatur, United States, Elk Grove Village, United States, Fort Lauderdale, United States, Great Falls, United States, Greensburg, United States and 10 more location s